Search
Abeona Therapeutics Inc
ABEOAdd to Watchlist
6.400USD
+0.350+5.79%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
363.94MMarket Cap
4.98P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+5.79%
5 Days
+14.08%
1 Month
+9.97%
6 Months
+20.53%
Year to Date
+21.44%
1 Year
+8.66%
Key Figures
6.090Open
6.420High
1.40MVolume
4.98P/E TTM
LossP/E Dynamic
--Dividend TTM
2.46%Turnover Ratio
6.050Prev. Close
6.000Low
5.58MTurnover
LossP/E Static
2.51P/B
0.00%Div Yield TTM
44.41%ROA
7.54052wk High
1.19Volume Ratio
-63.73MNet Profit
56.87MShares
1.2844EPS TTM
1.34Beta
70.99%ROE
4.00052wk Low
6.94%Amplitude
69.08%Gross Margin
363.94MMarket Cap
1.33Reward/Risk
2.97%Risk Rate
TradingKey Stock Score of Abeona Therapeutics Inc
Currency: USD Updated: 2026-07-02Key Insights
Abeona Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 44 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 19.71.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Abeona Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Abeona Therapeutics Inc Highlights
StrengthsRisks
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 66.29% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 5.82M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 4.98, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 40.30M shares, decreasing 14.33% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 49.49K shares of this stock.
Analyst Rating
Based on
6
analysts
Strong Buy
Current Rating
19.714
Target Price
+225.86%
Upside Space
Abeona Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Abeona Therapeutics Inc Info
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).
Ticker SymbolABEO
CompanyAbeona Therapeutics Inc
CEOSeshadri (Vishwas)
Websitehttps://abeonatherapeutics.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Abeona Therapeutics Inc (ABEO)?
The current price of Abeona Therapeutics Inc (ABEO) is 6.40.
What is the symbol of Abeona Therapeutics Inc?
The ticker symbol of Abeona Therapeutics Inc is ABEO.
What is the 52-week high of Abeona Therapeutics Inc?
The 52-week high of Abeona Therapeutics Inc is 7.54.
What is the 52-week low of Abeona Therapeutics Inc?
The 52-week low of Abeona Therapeutics Inc is 4.00.
What is the market capitalization of Abeona Therapeutics Inc?
The market capitalization of Abeona Therapeutics Inc is 363.94M.
Is Abeona Therapeutics Inc (ABEO) currently rated as Buy, Hold, or Sell?
According to analysts, Abeona Therapeutics Inc (ABEO) has an overall rating of STRONG BUY, with a price target of 19.71.
What is the Earnings Per Share (EPS TTM) of Abeona Therapeutics Inc (ABEO)?
The Earnings Per Share (EPS TTM) of Abeona Therapeutics Inc (ABEO) is 1.34.